Literature DB >> 8846274

Regional variations in skin perfusion and skin thickness may contribute to varying efficacy of topical, local anaesthetics in neonates.

B A Larsson1, M Norman, P Bjerring, H Egekvist, H Lagercrantz, G L Olsson.   

Abstract

The national Swedish screening programme for inborn errors of metabolism includes blood sampling from all neonates. Heel lancing has hitherto been the method of choice for these screening tests. Studies have recently been done to find out whether the use of EMLA can alleviate pain caused by heel lancing. EMLA had little, if any effect when applied to the heel of full term babies. Similar results were reported concerning preterm infants. Other authors have found that differences in skin thickness or in skin blood perfusion may influence the effect of EMLA. The aim of this study was to establish whether differences in skin thickness or in skin blood perfusion were present in three regions: the forehead, the dorsum of the hand and the heel. Ten healthy full term neonates were included in the study on skin perfusion. Measurements were made with a laser Doppler flux meter. Twenty-seven healthy full term neonates were included for measurements of skin thickness using a high frequency B-mode ultrasonic meter. The heel skin perfusion was two to three times higher than the skin perfusion at the dorsum of the hand and at the forehead but there was no significant difference when comparing skin thickness of the heel with the dorsum of the hand and the forehead. A rapid clearance of a topically applied local anaesthetic, due to high cutaneous blood flow, may explain why EMLA seems to be of little value when it is applied to the neonatal heel.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8846274     DOI: 10.1111/j.1460-9592.1996.tb00370.x

Source DB:  PubMed          Journal:  Paediatr Anaesth        ISSN: 1155-5645            Impact factor:   2.556


  16 in total

1.  Topical use of local anesthetics in neonates.

Authors:  C M Essink-Tjebbes; Y A Hekster; K D Liem; R T van Dongen
Journal:  Pharm World Sci       Date:  1999-08

Review 2.  Pharmacological therapy for analgesia and sedation in the newborn.

Authors:  K J S Anand; R W Hall
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-11       Impact factor: 5.747

3.  Analgesia in preterm newborns: the comparative effects of sucrose and glucose.

Authors:  Fusun Okan; Asuman Coban; Zeynep Ince; Zuhal Yapici; Gulay Can
Journal:  Eur J Pediatr       Date:  2007-01-04       Impact factor: 3.183

4.  Randomised controlled trial of eutectic mixture of local anaesthetics cream for venepuncture in healthy preterm infants.

Authors:  A B Acharya; P C Bustani; J D Phillips; N A Taub; R M Beattie
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-03       Impact factor: 5.747

Review 5.  Anesthesia and analgesia in the NICU.

Authors:  R Whit Hall
Journal:  Clin Perinatol       Date:  2012-03       Impact factor: 3.430

Review 6.  A critical review of the topical local anesthetic amethocaine (Ametop) for pediatric pain.

Authors:  Lisa O'Brien; Anna Taddio; Dorothy A Lyszkiewicz; Gideon Koren
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

7.  Does topical amethocaine gel reduce pain from heel prick blood sampling in premature infants? A randomized double-blind cross-over controlled study.

Authors:  Amita Patel; Barbara Czerniawski; Shari Gray; Eric Lui
Journal:  Paediatr Child Health       Date:  2003-04       Impact factor: 2.253

Review 8.  Pain management in newborns.

Authors:  Richard W Hall; Kanwaljeet J S Anand
Journal:  Clin Perinatol       Date:  2014-10-07       Impact factor: 3.430

9.  Topical amethocaine gel for pain relief of heel prick blood sampling: a randomised double blind controlled trial.

Authors:  A Jain; N Rutter; M Ratnayaka
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-01       Impact factor: 5.747

10.  Drugs of choice for sedation and analgesia in the neonatal ICU.

Authors:  R Whit Hall; Rolla M Shbarou
Journal:  Clin Perinatol       Date:  2009-03       Impact factor: 3.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.